- Trials with a EudraCT protocol (24)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (1)
24 result(s) found for: Calcium Homeostasis.
Displaying page 1 of 2.
EudraCT Number: 2008-002280-14 | Sponsor Protocol Number: L00006 CP 403 3A | Start Date*: 2008-07-18 | |||||||||||
Sponsor Name:Pierre Fabre Médicament | |||||||||||||
Full Title: Comparative study of the effect of 4-week treatment with ossein-hydroxyapatite compound versus calcium carbonate on bone biomarkers in young women with low calcium intake. Prospective, monocenter, ... | |||||||||||||
Medical condition: The Active substance of Osteopor is Ossein Hydroxyapatite. Treatment of processes characterized by decalcification: osteoporosis, Cushing syndrome, thyrotoxicosis. | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Female | ||||||||||||
Trial protocol: FR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2013-001267-23 | Sponsor Protocol Number: PAT13300CCD | Start Date*: 2013-06-19 | ||||||||||||||||
Sponsor Name:Pharma Patent Kft | ||||||||||||||||||
Full Title: Open label multicentric study to evalute the safety and efficacy of CitrokalciumD 300 mg/300 NE tablets in patients assessed deficiency for supplementation of calcium and vitamin D. | ||||||||||||||||||
Medical condition: Vitamin D and calcium deficiency | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Female | |||||||||||||||||
Trial protocol: HU (Completed) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2010-018553-35 | Sponsor Protocol Number: SMF1482 | Start Date*: 2010-05-03 | |||||||||||
Sponsor Name:Gambro Lundia AB | |||||||||||||
Full Title: SMARTCIT - A NOVEL CITRATE BASED ANTICOAGULATION | |||||||||||||
Medical condition: Acute renal failure | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2008-000606-36 | Sponsor Protocol Number: 84421383 | Start Date*: 2008-04-07 | |||||||||||
Sponsor Name:Aarhus University Hospital, Dept of Endocrinology and Metabolism C | |||||||||||||
Full Title: Treatment of hypoparathyroidism with subcutaneous PTH (1-84) injections: effects on muscle function and quality of life | |||||||||||||
Medical condition: Hypoparathyroidism | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2006-001998-25 | Sponsor Protocol Number: BLO K025 | Start Date*: 2006-09-29 | |||||||||||
Sponsor Name:Takeda Pharma GmbH | |||||||||||||
Full Title: Double-blind, randomised trial to investigate the antihypertensive and metabolic effects of candesartan in insulin-resistant obese patients with a hypertension not adequately controlled by previous... | |||||||||||||
Medical condition: Insulin-resistant obese patients with a hypertension not adequately controlled by previous beta-blocker or calcium channel blocker | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2013-002269-21 | Sponsor Protocol Number: 01.00240 | Start Date*: 2013-12-06 |
Sponsor Name:Department of Physiology and Cardiothoracic Surgery, Faculty of Medicine, University of Porto | ||
Full Title: Metformin in diastolic dysfunction of metabolic syndrome | ||
Medical condition: Diastolic dysfunction in non-diabetic patients with metabolic syndrome | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: PT (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2014-003645-10 | Sponsor Protocol Number: 2014-LSB | Start Date*: 2014-11-27 |
Sponsor Name:Department of Endocrinology and Internal Medicine | ||
Full Title: Physiological interactions between the adrenal- and the parathyroid glands described by controlled clinical trials | ||
Medical condition: Secondary hyperparathyrodism due to Vitamin D deficiency | ||
Disease: | ||
Population Age: Elderly | Gender: Female | |
Trial protocol: DK (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2011-004670-28 | Sponsor Protocol Number: 2011-AKA | Start Date*: 2012-04-25 | |||||||||||
Sponsor Name:Aarhus University Hospital, Dept of Endocrinology and Internel Medicine (MEA) | |||||||||||||
Full Title: Treatment of osteopenia with melatonin: Effects on BMD, muscle strength and quality of life | |||||||||||||
Medical condition: Osteoporosis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: DK (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-000508-40 | Sponsor Protocol Number: PAT17-LOADS | Start Date*: 2018-06-11 | |||||||||||
Sponsor Name:Pharma Patent Kft. | |||||||||||||
Full Title: Controlled randomized open label clinical study to compare the efficacy and the safety of the loading dose schedules of Vitamin D3 (colecalciferol) 30,000 IU product in deficient patients | |||||||||||||
Medical condition: Vitamin-D deficient patients | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2006-006692-20 | Sponsor Protocol Number: independant Trial (TOMIBA-TRIAL01) | Start Date*: 2007-09-06 |
Sponsor Name:St. Vincent Hospital, Medical Department II | ||
Full Title: The TOMIBA study Treatment of Osteoporotic Men With Intravenous Ibandronate An open-label, single-center, prospective Phase III study | ||
Medical condition: Osteoporosis in Men | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male | |
Trial protocol: AT (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2008-005063-34 | Sponsor Protocol Number: CL1-11-040 | Start Date*: 2009-09-14 | |||||||||||
Sponsor Name:NPS Pharmaceuticals, Inc. | |||||||||||||
Full Title: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Investigate the Use of NPSP 558, a Recombinant Human Parathyroid Hormone [rhPTH(1-84)] for the Treatment of Adults with Hypoparathyr... | |||||||||||||
Medical condition: Hypoparathyroidism | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) DK (Completed) BE (Completed) GB (Completed) IT (Completed) LT (Completed) HU (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-003183-75 | Sponsor Protocol Number: 752/11 | Start Date*: 2012-01-23 | |||||||||||
Sponsor Name:POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI | |||||||||||||
Full Title: the role of vitamin D supplementation in the prevention of cardiovascular risk factors | |||||||||||||
Medical condition: Obesity | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-001983-49 | Sponsor Protocol Number: UX023-CL205 | Start Date*: 2019-10-10 | |||||||||||
Sponsor Name:Ultragenyx Pharmaceutical Inc | |||||||||||||
Full Title: An Open-Label, Phase 2 Study to Assess the Safety, Pharmacodynamics, and Efficacy of KRN23 in Children from 1 to 4 Years Old with X-linked Hypophosphatemia (XLH) | |||||||||||||
Medical condition: XLH is a disorder of hypophosphatemia, renal phosphate wasting, and the most common inheritable form of rickets. In XLH patients, excess circulating fibroblast growth factor (FGF23) impair phosphat... | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: Outside EU/EEA | |||||||||||||
Trial results: View results |
EudraCT Number: 2005-001511-22 | Sponsor Protocol Number: 004 | Start Date*: 2005-08-24 | |||||||||||
Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., | |||||||||||||
Full Title: A 5-Year Open Label Extension to: A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety, Tolerability, and Efficacy of Odanacatib (MK-0822) in the Treatment of Postmenopausal W... | |||||||||||||
Medical condition: Postmenopausal Osteoporosis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: SE (Completed) DK (Completed) GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-006121-65 | Sponsor Protocol Number: 65411807 | Start Date*: 2021-08-31 | |||||||||||
Sponsor Name:Odense University Hospital | |||||||||||||
Full Title: STUDY PROTOCOL: A multi-centre, randomized, double-blinded, placebo controlled 1-year study to compare the effect of hydrocortisone and palcebo in patients with partial adrenal insufficiency after ... | |||||||||||||
Medical condition: To investigate the effects of hydrocortisone replacement in participants with previous PMR and GCA, who are in GC-free remission and exhibit biochemical evidence of mild to moderate adrenal insuffi... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-003190-26 | Sponsor Protocol Number: BUR03 | Start Date*: 2020-12-21 | |||||||||||
Sponsor Name:Julius-Maximilian University of Würzburg | |||||||||||||
Full Title: An investigator-sponsored Phase 3b Open-label Study of Anti-FGF23 Antibody Burosumab (KRN23) in Adult Patients with X-linked Hypophosphatemia (XLH) in GERmany - BurGER | |||||||||||||
Medical condition: X-linked hypophosphatemia (XLH) is a disorder of renal phosphate wasting, and the most common heritable form of rickets. In XLH patients, high circulating levels of fibroblast growth factor 23 (FGF... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-000469-19 | Sponsor Protocol Number: BUR-CL207 | Start Date*: 2020-11-03 | |||||||||||
Sponsor Name:Kyowa Kirin Pharmaceutical Development Ltd. | |||||||||||||
Full Title: A Phase 1/2, Open-label, Multicenter, Non-randomized Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of Burosumab in Pediatric Patients from Birth to Less than 1 Year of Ag... | |||||||||||||
Medical condition: XLH is a rare, genetic disorder that is serious, chronically debilitating and represents an unmet medical need. This genetic deficiency is estimated to occur in about 1:20,000 live births (Burnett ... | |||||||||||||
|
|||||||||||||
Population Age: Newborns, Infants and toddlers, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) FR (Ongoing) DE (Prematurely Ended) SE (Completed) AT (Completed) IT (Ongoing) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-000600-29 | Sponsor Protocol Number: UX023-CL301 | Start Date*: 2016-09-15 | |||||||||||
Sponsor Name:Ultragenyx Pharmaceuticals Inc | |||||||||||||
Full Title: A Randomized, Open-Label, Phase 3 Study to Assess the Efficacy and Safety of KRN23 Versus Oral Phosphate and Active Vitamin D Treatment in Pediatric Patients with X-linked Hypophosphatemia (XLH) | |||||||||||||
Medical condition: X-linked hypophosphatemia (XLH) is a disorder of renal phosphate wasting, defective bone mineralisation, and impaired growth plate or endochondral ossification caused by inactivating mutations in t... | |||||||||||||
|
|||||||||||||
Population Age: Children, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Prematurely Ended) IE (Completed) DE (Completed) ES (Prematurely Ended) SE (Completed) GB (Completed) IT (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-003177-58 | Sponsor Protocol Number: SPIOMET4HEALTH | Start Date*: 2022-05-12 | |||||||||||
Sponsor Name:Fundació Sant Joan de Déu (FSJD) | |||||||||||||
Full Title: A Phase II, randomised, multi-centric, multi-national clinical trial to evaluate the efficacy, tolerability, and safety of a fixed dose combination of Spironolactone, Pioglitazone & Metformin (SPIO... | |||||||||||||
Medical condition: Polycystic Ovary Syndrome (PCOS) | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults | Gender: Female | ||||||||||||
Trial protocol: AT (Ongoing) NO (Ongoing) IT (Ongoing) ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-005529-11 | Sponsor Protocol Number: UX023-CL303 | Start Date*: 2016-02-01 | |||||||||||
Sponsor Name:Ultragenyx Pharmaceutical Inc. | |||||||||||||
Full Title: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study with Open-Label Extension to Assess the Efficacy and Safety of KRN23 in Adults with X-linked Hypophosphatemia (XLH) | |||||||||||||
Medical condition: XLH is a disorder of hypophosphatemia, renal phosphate wasting, and the most common inheritable form of rickets. In XLH patients, excess circulating fibroblast growth factor (FGF23) impair phospha... | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) IE (Completed) FR (Completed) DK (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
Query did not match any studies.